Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TGM-312-SC01 in healthy participants and adults with metabolic dysfunction-associated steatohepatitis
ISRCTN65253349Phase 2Recruiting
- Sponsor
- Tangram Therapeutics
- Start
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of TGM-312 in metabolic dysfunction-associated steatohepatitis (MASH) (4 arms), sponsored by Tangram Therapeutics. Primary endpoint: Safety and tolerability. Started Feb 2026; status: recruiting.
02
Drugs
TGM-312
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ISRCTN65253349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN65253349.